Breaking the Adenosine Barrier: ENT1 Inhibition as a Novel Strategy to Restore Anti-Cancer T Cell Function
Targeting Intracellular Adenosine Uptake Offers New Hope for Overcoming Tumor Immunosuppression
TribeMD
6 min read
July 28, 2025
Carregando conteúdo…
Oncology
Sources
- Sanders, T.J., et al. (2025). Inhibition of ENT1 relieves intracellular adenosine-mediated T cell suppression in cancer. Nature Immunology. https://doi.org/10.1038/s41590-025-02153-3.
Highlights
TribeMD
ASCO GU® 2026
TribeMD
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
TribeMD
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care
TribeMD
ASCO GU® 2026
TribeMD
Trastuzumab deruxtecan (T-DXd) Provides Significant Clinical Benefit Over Trastuzumab emtansine (T-DM1), Marking a Potential Shift in the Therapeutic Standard for HER2+ Breast Cancer
TribeMD
SnackableHealth™ | From Intervention to Prevention: How Secondary Prevention Clinics Are Redefining Post-ACS Care